Wedbush also issued estimates for Sarepta Therapeutics’ Q4 2016 earnings at ($1.18) EPS, FY2016 earnings at ($5.08) EPS, Q1 2017 earnings at ($0.80) EPS, Q2 2017 earnings at ($0.85) EPS, Q3 2017 earnings at ($0.78) EPS, Q4 2017 earnings at ($0.84) EPS, FY2017 earnings at ($3.27) EPS, FY2018 earnings at ($2.01) EPS, FY2019 earnings at $0.70 EPS and FY2020 earnings at $2.18 EPS. The share price is now 87.46 percent versus its SMA20, 111.33 percent versus its SMA50, and 154.94 percent versus its SMA200. The forecast of 10 polled investment analysts covering the stock advises investors to Buy stake in the company. Teacher Retirement System of Texas now owns 6,034 shares of the company’s stock worth $115,000 after buying an additional 724 shares during the last quarter. At present, 11 analysts recommended Holding these shares while 3 recommended sell, according to FactSet data. “Underperform” verdict was shared by 0 analyst and “Outperform” recommendation was issued by 5 analyst.
Advertisement
It looks like Sarepta Therapeutics Inc (NASDAQ: SRPT)’s Eteplirsen may not be out of the woods just yet. The latest trading activity of 8.34 Million shares is above its average volume of 3.08 Million shares. The share price of $28.11 is at a distance of 51.78 percent from its 52-week low and down -47.35 percent versus its peak. The company’s net profit margin has achieved the current level of 0% and possesses 0% gross margin.
If BioMarin’s appeal is successful, the Novato, CA-based company could gain royalties from Sarepta, but BioMarin isn’t likely to resume development of its own DMD drug, BMO Capital Markets noted. Over the one year trading period, the stock has a high price of $58.87 and its low is recorded at $8.00. Wedbush has a “Outperform” rating and a $66.00 price target on the stock. The Insider ownership stake in the company is 1.00% while the ATR stands at 0.42. Its RSI (Relative Strength Index) reached 55.29.
Sarepta Therapeutics, Inc.’s (SRPT) has traded at distance of 111.33% from its 50-day simple moving average and moved at distance of 154.94% from its 200-day simple moving average while exchanged at distance of 87.46% from its 20-day simple moving average.
Advertisement
A number of Wall Street analysts stated their opinion on the stock. 1 analysts call it Overweight, while 0 think it is Underweight. Also, SVP David T. Howton sold 9,304 shares of Sarepta Therapeutics stock in a transaction that occurred on Monday, September 19th. The company has an Average Rating of 2.71 based on Thomson Reuters I/B/E/S scale of 1-5.
